Novo Nordisk Shares Face Mounting Pressure as Growth Forecasts Diminish

The Danish pharmaceutical company renowned for its diabetes and obesity treatments finds itself navigating turbulent waters. Novo Nordisk has been compelled to reduce its financial projections for the fourth time this year, raising significant concerns among investors who had placed their confidence in the growth narrative of its GLP-1 medications. This repeated downward revision pattern indicates deeper challenges that extend beyond temporary market fluctuations.

Market analysts are observing a troubling trend in the company’s guidance adjustments. The anticipated operational profit growth for 2025 has been trimmed from the previous range of 4-10% down to just 4-7%. Even more substantial was the reduction in revenue growth expectations, which narrowed from 8-14% to Read more...